Participated · Series B · Jul 2026

Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

Participated · Series B · May 2026

Xpanner’s flagship X1 Kit retrofits customers’ existing construction machines with hardware and software that enable autonomous operation, allowing task-specific automation licenses for piling, material handling, trenching and grading. The company sells automation through an AaaS (Automation-as-a-Service) subscription model while some customers remain on a perpetual modular model that pairs one-time X1 Kit purchases with software. Customers include Mortenson, Black & Veatch, and QCells. Originally founded in South Korea in 2020, Xpanner moved its headquarters to Santa Fe Springs, California in 2023. The company reported revenue growth from $3 million in 2023 to $7 million in 2024 and $21 million in 2025, with $8 million in revenue and $1 million in EBIT in Q1 2026, and it is targeting $60 million in ARR by year-end while maintaining gross margins above 80%. Xpanner achieved monthly break-even in 2025 and is on track for full-year profitability, and it is expanding product development and into adjacent construction verticals.

Participated · Series C · Apr 2026

Mediwhale develops AI-driven retinal imaging analysis tools that predict cardiovascular risk from a single eye image, marketed under names including Dr. Noon CVD. The company is focused on commercializing those AI biomarkers and expanding partnerships with imaging hardware vendors such as iCare. Mediwhale is actively pursuing FDA De Novo clearance to access the U.S. market and has publicly stated plans to prepare for a public listing, targeting KOSDAQ in 2027 while positioning for a broader U.S. listing narrative. Financially, the firm has raised roughly ₩51.2 billion (about $34M) to date, most recently securing ₩20 billion in a Series C. The company emphasizes scaling global commercialization and regulatory readiness as near-term priorities.

Participated · Equity · Mar 2026

Autonomous A2Z develops autonomous vehicle technologies with a hybrid engineering approach that combines rule-based algorithms and AI-driven decision systems aimed at achieving Level 4 autonomy. The company operates a research center in Pyeongchon, Gyeonggi, and runs autonomous mobility projects in markets including Singapore (in partnership with Grab), the United Arab Emirates, and Japan, where it has begun robotaxi trials. It has accumulated total funding of 122.5 billion won following the recent 40.5 billion won pre-IPO round and is preparing for a Kosdaq listing. Planned uses of capital include expanding domestic and international projects and procuring sensors, controllers, and vehicle components. Autonomous A2Z is preparing to participate in a large-scale pilot program led by the South Korea Ministry of Transport. The company says it aims to accelerate commercial deployment of Level 4 driverless vehicles and to build a global data network to support that goal.

Participated · Series A · Jan 2026

Founded in 2021 in Seoul, Coxwave specializes in AI product analytics and reliability solutions for conversational AI. Its flagship platform, Coxwave Align, delivers user analytics and feedback-driven evaluations, allowing operators to track metrics such as conversation satisfaction and interaction patterns. The company is expanding the platform to include real-time monitoring, anomaly detection, and automated intervention, effectively serving as guardrails for AI agents in production. Beyond software, Coxwave offers AX consulting services that have supported e-commerce, public sector, and professional-services projects for global clients including PwC India, Meta, Microsoft, and Economic Times. Partnerships with Anthropic, OpenAI, and NVIDIA underscore its technical depth; the firm co-hosted Builder Summits and Hackathons with these partners in 2025 and was accepted into the government-backed Scale-Up TIPS R&D program in December. Coxwave claims the first successful exit of a generative AI product in Korea in 2023, further validating its expertise. Following the latest capital infusion, the company’s total funding stands at $8.6 million, which it plans to channel into strengthening AI reliability technology and scaling its consulting arm.